In conclusion, TNFSF4 is a potential immunotherapy target due to its aberrant expression pattern in breast carcinoma, and this protein was even found to be overexpressed in carcinomas without ERBB2, ESR1, or PGR1 amplification and those without either KRAS or TP53 mutation and amplification. Here, TP53 is linked to breast carcinoma.